Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2000-07-11
2004-03-30
Wehbe′, Anne M. (Department: 1632)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S388100, C530S388150, C424S130100, C424S132100, C424S141100, C424S147100, C424S145100
Reexamination Certificate
active
06713610
ABSTRACT:
TECHNICAL FIELD
The invention relates to the field of immunology, and in particular Lo the production of antibodies. More specifically, it concerns producing such antibodies by a process which includes the step of immunizing a transgenic animal with an antigen to which antibodies are desired. The transgenic animal has been modified so as to produce human, as opposed to endogenous, antibodies.
BACKGROUND ART
PCT application WO 94/02602, published Feb. 3, 1994, and incorporated herein by reference, describes in detail the production of transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than endogenous antibodies in response to antigenic challenge. Briefly, the endogenous loci encoding the heavy and light immunoglobulin chains are incapacitated in the transgenic hosts and loci encoding human heavy and light chain proteins are inserted into the genome. In general, the animal which provides all the desired modifications is obtained by cross breeding intermediate animals containing fewer than the full complement of modifications. The preferred embodiment of nonhuman animal described in the specification is a mouse. Thus, mice, specifically, are described which, when administered immunogens, produce antibodies with human variable regions, including fully human antibodies, rather than murine antibodies that are immunospecific for these antigens.
The availability of such transgenic animals makes possible new approaches to the production of fully human antibodies. Antibodies with various immunospecificities are desirable for therapeutic and diagnostic use. Those antibodies intended for human therapeutic and in vivo diagnostic use, in particular, have been problematic because prior art sources for such antibodies resulted in immunoglobulins bearing the characteristic structures of antibodies produced by nonhuman hosts. Such antibodies tend to be immunogenic when used in humans.
The availability of the nonhuman, immunogen responsive transgenic animals described in the above-referenced WO 94/02602 make possible convenient production of human antibodies without the necessity of employing human hosts.
DISCLOSURE OF THE INVENTION
The invention is directed to methods to produce human antibodies by a process wherein at least one step of the process includes immunizing a transgenic nonhuman animal with the desired antigen. The modified animal fails to produce endogenous antibodies, but instead produces B-cells which secrete fully human immunoglobulins. The antibodies produced can be obtained from the animal directly or from immortalized B-cells derived from the animal. Alternatively, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly or modified to obtain analogs of antibodies such as, for example, single chain F
v
molecules.
Thus, in one aspect, the invention is directed to a method to produce a fully human immunoglobulin to a specific antigen or to produce an analog of said immunoglobulin by a process which comprises immunizing a nonhuman animal with the antigen under conditions that stimulate an immune response. The nonhuman animal is characterized by being substantially incapable of producing endogenous heavy or light immunoglobulin chain, but capable of producing immunoglobulins with both human variable and constant regions. In the resulting immune response, the animal produces B cells which secrete immunoglobulins that are fully human and specific for the antigen. The human immunoglobulin of desired specificity can be directly recovered from the animal, for example, from the serum, or primary B cells can be obtained from the animal and immortalized. The immortalized B cells can be used directly as the source of human antibodies or, alternatively, the genes encoding the antibodies can be prepared from the immortalized B cells or from primary B cells of the blood or lymphoid tissue (spleen, tonsils, lymph nodes, bone marrow) of the immunized animal and expressed in recombinant hosts, with or without modifications, to produce the immunoglobulin or its analogs. In addition, the genes encoding the repertoire of immunoglobulins produced by the immunized animal can be used to generate a library of immunoglobulins to permit screening for those variable regions which provide the desired affinity. Clones from the library which have the desired characteristics can then be used as a source of nucleotide sequences encoding the desired variable regions for further manipulation to generate antibodies or analogs with these characteristics using standard recombinant techniques.
In another aspect, the invention relates to an immortalized nonhuman B cell line derived from the above described animal. In still another aspect, the invention is directed to a recombinant host cell which is modified to contain the gene encoding either the human immunoglobulin with the desired specificity, or an analog thereof which exhibits the same specificity.
In still other aspects, the invention is directed to antibodies or antibody analogs prepared by the above-described methods and to recombinant materials for their production.
In still other aspects, the invention is directed to antibodies which are immunospecific with respect to particular antigens set forth herein and to analogs which are similarly immunospecific, as well as to the recombinant materials useful to production of these antibodies.
REFERENCES:
patent: 4950599 (1990-08-01), Bertling
patent: 4959313 (1990-09-01), Taketo
patent: 5204244 (1993-04-01), Fell et al.
patent: 5286647 (1994-02-01), Handley et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 0 298 807 (1989-01-01), None
patent: 0 315 062 (1989-05-01), None
patent: 0 322 240 (1989-06-01), None
patent: 0 459 372 (1991-12-01), None
patent: 0 463 151 (1992-01-01), None
patent: WO 90/04036 (1990-04-01), None
patent: WO 91/00906 (1991-01-01), None
patent: WO 91/10741 (1991-07-01), None
patent: WO 92/03918 (1992-03-01), None
patent: WO 92/22645 (1992-12-01), None
patent: WO 93/05165 (1993-03-01), None
patent: WO 93/12227 (1993-06-01), None
patent: WO 94/00569 (1994-01-01), None
patent: WO 94/02602 (1994-02-01), None
patent: WO 94/25585 (1994-11-01), None
patent: WO 96/34096 (1996-10-01), None
Li et. al.; The I Binding Specificity of Human . . . and Complementary Determining Region 3, 1996, J. Moi. Biol. 256:577-589.*
Albertson, et al., “Construction and characterization of a yeast artificial chromosome library containing seven haploid human genome equivalents,”Proc. Natl. Acad. Sci. U. S. A.87:4256-4260 (1990).
Aldhous, “Transgenic mice display a class (switching) act,”Science262:1212-1213 (1993).
Ayres, et al., “Sequence homology requirements for intermolecular recombination in mammalian cells,”Proc. Natl. Acad. Sci. U.S.A.83:5199-5203 (1986).
Berman, et al., “Content and organization of the human Ig VHlocus: definition of three new Vhfamilies and linkage to the Ig Chlocus”EMBO J.7:727-738 (1988).
Blankenstein, et al., “Immunoglobulin Vhregion genes of the mouse are organized in overlapping clusters”Eur. J. Immunol.17:1351-1357 (1987).
Brinster, et al., “Introns increase transcriptional efficiency in trangenic mice,”Proc. Natl. Acad. Sci. U.S.A.85:836-840 (1988).
Brownstein, et al., “Isolation of single-copy human genes from a library of yeast artificial chromosomes”,Science244:1348-1351 (1989).
Bruggemann, et al., “A repertoire of monoclonal antibodies with human heavy chains from transgenic mice,”Proc. Natl. Acad. Sci. U.S.A.86:6709-6713 (1989).
Bruggemann, et al., “Construction, function and immunogenicity of recombinant monoclonal antibodies,”Behring Inst. Mitt.87:21-24 (1990).
Bruggemann, et al., “Human antibody production in transgenic mice: expression from 100 kb of the human IgH locus,”Eur. J. Immunol.21:1323-1326 (1991).
Bruggemann, et al., “Stategies for expressing human antibody repertoires in transgenic mice,”Immunology Today17:391-397 (1996).
Burke, et al., “Cloning of large
Brenner Daniel G.
Capon Daniel J.
Jakobovits Aya
Klapholz Sue
Kucherlapati Raju
LandOfFree
Human antibodies derived from immunized xenomice does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human antibodies derived from immunized xenomice, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human antibodies derived from immunized xenomice will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3272482